Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-05T05:12:43.384Z Has data issue: false hasContentIssue false
  • English
  • Français

Using diagnostic stewardship to reduce rates, healthcare expenditures and accurately identify cases of hospital-onset Clostridioides difficile infection

Published online by Cambridge University Press:  18 September 2020

Dipesh Solanky ,
Derek K. Juang ,
Scott T. Johns ,
Ian C. Drobish ,
Sanjay R. Mehta  and
Monika Kumaraswamy Open the ORCID record for Monika Kumaraswamy [Opens in a new window]
Dipesh Solanky*
Affiliation:
Department of Medicine, University of California San Diego, La Jolla, California Department of Medicine, VA San Diego Healthcare System, San Diego, California
Derek K. Juang
Affiliation:
Department of Medicine, University of California San Diego, La Jolla, California Department of Medicine, VA San Diego Healthcare System, San Diego, California
Scott T. Johns
Affiliation:
Department of Pharmacy, VA San Diego Healthcare System, San Diego, California
Ian C. Drobish
Affiliation:
Department of Medicine, University of California San Diego, La Jolla, California Department of Medicine, VA San Diego Healthcare System, San Diego, California
Sanjay R. Mehta
Affiliation:
Department of Medicine, University of California San Diego, La Jolla, California Department of Medicine, VA San Diego Healthcare System, San Diego, California Infectious Diseases Section, VA San Diego Healthcare System, San Diego, California
Monika Kumaraswamy*
Affiliation:
Department of Medicine, University of California San Diego, La Jolla, California Department of Medicine, VA San Diego Healthcare System, San Diego, California Infectious Diseases Section, VA San Diego Healthcare System, San Diego, California Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), University of California San Diego, La Jolla, California
*
Author for correspondence: Monika Kumaraswamy, E-mail: [email protected]. Or Dipesh Solanky, E-mail: [email protected]
Author for correspondence: Monika Kumaraswamy, E-mail: [email protected]. Or Dipesh Solanky, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Lack of judicious testing can result in the incorrect diagnosis of Clostridioides difficile infection (CDI), unnecessary CDI treatment, increased costs and falsely augmented hospital-acquired infection (HAI) rates. We evaluated facility-wide interventions used at the VA San Diego Healthcare System (VASDHS) to reduce healthcare-onset, healthcare-facility–associated CDI (HO-HCFA CDI), including the use of diagnostic stewardship with test ordering criteria.

Design:

We conducted a retrospective study to assess the effectiveness of measures implemented to reduce the rate of HO-HCFA CDI at the VASDHS from fiscal year (FY)2015 to FY2018.

Interventions:

Measures executed in a stepwise fashion included a hand hygiene initiative, prompt isolation of CDI patients, enhanced terminal room cleaning, reduction of fluoroquinolone and proton-pump inhibitor use, laboratory rejection of solid stool samples, and lastly diagnostic stewardship with C. difficile toxin B gene nucleic acid amplification testing (NAAT) criteria instituted in FY2018.

Results:

From FY2015 to FY2018, 127 cases of HO-HCFA CDI were identified. All rate-reducing initiatives resulted in decreased HO-HCFA cases (from 44 to 13; P ≤ .05). However, the number of HO-HCFA cases (34 to 13; P ≤ .05), potential false-positive testing associated with colonization and laxative use (from 11 to 4), hospital days (from 596 to 332), CDI-related hospitalization costs (from $2,780,681 to $1,534,190) and treatment cost (from $7,158 vs $1,476) decreased substantially following the introduction of diagnostic stewardship with test criteria from FY2017 to FY2018.

Conclusions:

Initiatives to decrease risk for CDI and diagnostic stewardship of C. difficile stool NAAT significantly reduced HO-HCFA CDI rates, detection of potential false-positives associated with laxative use, and lowered healthcare costs. Diagnostic stewardship itself had the most dramatic impact on outcomes observed and served as an effective tool in reducing HO-HCFA CDI rates.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 42 , Issue 1 , January 2021 , pp. 51 - 56
Check for updates
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

a

Authors of equal contribution.

References

Lyerly, DM, Krivan, HC, Wilkins, TD. Clostridium difficile: its disease and toxins. Clin Microbiol Rev 1988;1:1–18.CrossRefGoogle ScholarPubMed
Dubberke, ER, Olsen, MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012;55 suppl 2:S88–S92.CrossRefGoogle ScholarPubMed
Magill, SS, Edwards, JR, Bamberg, W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198–1208.CrossRefGoogle ScholarPubMed
Guh, AY, Mu, Y, Winston, LG, et al. Trends in US burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020;382:1320–1330.CrossRefGoogle Scholar
Polage, CR, Gyorke, CE, Kennedy, MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 2015;175:1792–1801.CrossRefGoogle ScholarPubMed
Kyne, L, Warny, M, Qamar, A, Kelly, CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390–397.CrossRefGoogle ScholarPubMed
McFarland, LV, Mulligan, ME, Kwok, RY, Stamm, WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204–210.CrossRefGoogle ScholarPubMed
Riggs, MM, Sethi, AK, Zabarsky, TF, Eckstein, EC, Jump, RL, Donskey, CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007;45:992–998.CrossRefGoogle ScholarPubMed
Buckel, WR, Avdic, E, Carroll, KC, Gunaseelan, V, Hadhazy, E, Cosgrove, SE. Gut check: Clostridium difficile testing and treatment in the molecular testing era. Infect Control Hosp Epidemiol 2014;36:217–221.CrossRefGoogle Scholar
Dubberke, ER, Han, Z, Bobo, L, et al. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J Clin Microbiol 2011;49:2887–2893.CrossRefGoogle ScholarPubMed
Peasah, SK, McKay, NL, Harman, JS, Al-Amin, M, Cook, RL. Medicare non-payment of hospital-acquired infections: infection rates three years post implementation. Medicare Medicaid Res Rev 2013;3.doi: 10.5600/mmrr.003.03.a08.CrossRefGoogle ScholarPubMed
National Healthcare Safety Network. Multidrug-resistant organism and Clostridioides difficile infection. Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/faqs/faq-mdro-cdi.html. Published 2019, Accessed August 4, 2019.Google Scholar
McDonald, LC, Gerding, DN, Johnson, S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1–e48.CrossRefGoogle Scholar
Fang, FC, Polage, CR, Wilcox, MH. Point–counterpoint: what is the optimal approach for detection of Clostridium difficile infection? J Clin Microbiol 2017;55:670–680.CrossRefGoogle ScholarPubMed
Planche, TD, Davies, KA, Coen, PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis 2013;13:936–945.CrossRefGoogle ScholarPubMed
Chapin, KC, Dickenson, RA, Wu, F, Andrea, SB. Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn 2011;13:395–400.CrossRefGoogle ScholarPubMed
Truong, CY, Gombar, S, Wilson, R, et al. Real-time electronic tracking of diarrheal episodes and laxative therapy enables verification of Clostridium difficile clinical testing criteria and reduction of Clostridium difficile infection rates. J Clin Microbiol 2017;55:1276–1284.CrossRefGoogle ScholarPubMed
Bilinskaya, A, Goodlet, KJ, Nailor, MD. Evaluation of a best practice alert to reduce unnecessary Clostridium difficile testing following receipt of a laxative. Diagn Microbiol Infect Dis 2018;92:50–55.CrossRefGoogle Scholar
Christensen, AB, Barr, VO, Martin, DW, et al. Diagnostic stewardship of C. difficile testing: a quasi-experimental antimicrobial stewardship study. Infect Control Hosp Epidemiol 2019;40:269–275.CrossRefGoogle ScholarPubMed
Crobach, MJ, Planche, T, Eckert, C, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 2016;22 suppl 4:S63–S81.CrossRefGoogle ScholarPubMed
McDonald, LC, Gerding, DN, Johnson, S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:987–994.CrossRefGoogle Scholar
Longtin, Y, Trottier, S, Brochu, G, et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis 2013;56:67–73.CrossRefGoogle Scholar
van den Berg, RJ, Bruijnesteijn van Coppenraet, LS, Gerritsen, HJ, Endtz, HP, van der Vorm, ER, Kuijper, EJ. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile–associated diarrhea in hospitalized patients. J Clin Microbiol 2005;43:5338–5340.CrossRefGoogle ScholarPubMed
Moon, HW, Kim, HN, Hur, M, Shim, HS, Kim, H, Yun, YM. Comparison of diagnostic algorithms for detecting toxigenic Clostridium difficile in routine practice at a tertiary referral hospital in Korea. PLoS One 2016;11:e0161139.CrossRefGoogle Scholar
Engstron-Melnyk, JA LC, Li, Y-C, et al. Diagnostic testing choice impacts hospital length of stay for patients diagnosed with C. difficile infections—real-world evidence from the US ASM Microbe; 2019; San Francisco, California.CrossRefGoogle Scholar
Bartlett, JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334–339.CrossRefGoogle ScholarPubMed
Hundsberger, T, Braun, V, Weidmann, M, Leukel, P, Sauerborn, M, von Eichel-Streiber, C. Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem 1997;244:735–742.CrossRefGoogle ScholarPubMed
Clostridioides difficile. Centers for Disease Control and Prevention website. https://www.cdc.gov/cdiff/index.html. Accessed August 4, 2020.Google Scholar
Supplementary material: File

Solanky et al. supplementary material

Tables S1-S2

Download Solanky et al. supplementary material(File)
File 23.8 KB